SITAGLIPTINE/METFORMINE HCL MYLAN TAB FO 50/1000MG

Active substance
SITAGLIPTINE/METFORMINE
Therapeutical formulation
TABLETTEN EN CAPSULES

€ 0.36 excluding delivery costs.

This drug is fully reimbursed by your health insurance company.

Aan de vergoeding van dit geneesmiddel zijn voorwaarden verbonden.

Own risk

€ 0.36

This is the amount charged to your deductible .

Strength
50/1000MG
Supplier
MYLAN B.V.
Available outside pharmacies
No
Remarks
  • This medicine is available by prescription only.
EU number
EU/1/21/1619/016

Conditions

Basic insurance

Sitagliptine, linagliptine, vildagliptine, saxagliptine en alogliptine Voorwaarde: uitsluitend voor een verzekerde met diabetes mellitus type 2 die niet behandeld kan worden met de combinatie van metformine en een sulfonylureumderivaat, geen insuline gebruikt en dit middel gebruikt als monotherapie of als een tweevoudige of drievoudige behandeling in combinatie met metformine en/of een sulfonylureumderivaat.

Insurer

Health insurers have the option for a number of drugs to reimburse only certain variants (e.g., based on their pricing or price agreements between health insurer and drug manufacturer). We call this preference policy. If your health insurer has a preference policy for one or more drugs, it is stated in your insurance policy. If there is a medical necessity to use a more expensive variant of the drug anyway, your health insurer may deviate from the preference policy. The way in which health insurers implement the preference policy varies from one health insurer to another. Therefore, for more information, consult your insurance policy or contact your health insurer.

Variants

See also